Sann-Joong-Kuey-Jian-Tang inhibits hepatocellular carcinoma Hep-G2 cell proliferation by increasing TNF-α, Caspase-8, Caspase- 3 and Bax but by decreasing TCTP and Mcl-1 expression in vitro.

Abstract

Hepatic cancer remains a challenging disease and there is a need to identify new treatments. Sann-Joong-Kuey-Jian-Tang (SJKJT), a traditional medicinal prescription, has been used to treat lymphadenopathy and exhibits cytotoxic activity in many types of human cancer cells. Our previous studies revealed that SJKJT is capable of inhibiting colon cancer colo 205 cells by inducing autophagy and apoptosis. However, the effects and molecular mechanisms of SJKJT in human hepatocellular carcinoma have not been clearly elucidated. In the present study we evaluated the effects of SJKJT in human hepatic cellular carcinoma Hep-G2 cells. The cytotoxicity of SJKJT in Hep-G2 cells was measured by MTT assay. The cell cycles were analyzed by fluorescence‑activated cell sorting (FACS). The protein expression of translationally controlled tumor protein (TCTP), Mcl-1, Fas, TNF-α, Caspase-8, Caspase-3 and Bax in Hep-G2 cells treated with SJKJT was evaluated by western blotting. The protein expression of Caspase-3 was also detected by immunofluorescence staining. The results showed that SJKJT inhibits Hep-G2 cells in a time- and dose‑dependent manner. During SJKJT treatment for 48 and 72 h, the half-maximum inhibitory concentration (IC50) was 1.48 and 0.94 mg/ml, respectively. The FACS results revealed that increased doses of SJKJT were capable of increasing the percentage of cells in the sub-G1 phase. Immunofluorescence staining showed that Hep-G2 treated with SJKJT had increased expression of Caspase-3. The western blot results showed that the protein expression of Fas, TNF-α, Caspase-8, Caspase- 3 and Bax was upregulated, but that of TCTP and Mcl-1 was downregulated in Hep-G2 cells treated with SJKJT. In conclusion, these findings indicated that SJKJT inhibits Hep-G2 cells. One of the molecular mechanisms responsible for this may be the increased Fas, TNF-α, Caspase-8, Caspase- 3 and Bax expression; another mechanism may be via decreasing TCTP and Mcl-1 expression in order to induce apoptosis.

• Authors: Yao-Li Chen, Meng-Yi Yan, Su-Yu Chien, Shou-Jen Kuo, Dar-Ren Chen, Chun-Yuan Cheng, Chin-Cheng Su
• Journal: Molecular medicine reports (Mol Med Rep) Vol. 7 Issue 5 Pg. 1487-93 (May 2013) ISSN: 1791-3004 [Electronic] Greece
• PMID: 23525225 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Biomarkers, Tumor
• Drugs, Chinese Herbal
• FADD protein, human
• FAS protein, human
• Fas-Associated Death Domain Protein
• Myeloid Cell Leukemia Sequence 1 Protein
• Proto-Oncogene Proteins c-bcl-2
• TPT1 protein, human
• Tumor Necrosis Factor-alpha
• Tumor Protein, Translationally-Controlled 1
• bcl-2-Associated X Protein
• fas Receptor
• sann-joong-kuey-jian-tang
• Caspase 3
• Caspase 8
• Caspases

Topics

• Apoptosis (drug effects)
• Biomarkers, Tumor (metabolism)
• Carcinoma, Hepatocellular (drug therapy, enzymology, pathology)
• Caspase 3 (metabolism)
• Caspase 8 (metabolism)
• Caspases (metabolism)
• Cell Cycle (drug effects)
• Cell Death (drug effects)
• Cell Proliferation (drug effects)
• Cell Survival (drug effects)
• Drug Screening Assays, Antitumor
• Drugs, Chinese Herbal (pharmacology, therapeutic use)
• Fas-Associated Death Domain Protein (metabolism)
• Hep G2 Cells
• Humans
• Immunohistochemistry
• Liver Neoplasms (drug therapy, enzymology, pathology)
• Myeloid Cell Leukemia Sequence 1 Protein
• Proto-Oncogene Proteins c-bcl-2 (metabolism)
• Tumor Necrosis Factor-alpha (metabolism)
• Tumor Protein, Translationally-Controlled 1
• bcl-2-Associated X Protein (metabolism)
• fas Receptor (metabolism)